FY2026 Earnings Forecast for Biogen Issued By HSBC

Biogen Inc. (NASDAQ:BIIB) – Equities research analysts at HSBC issued their FY2026 earnings per share estimates for shares of Biogen in a report released on Friday, April 17th. HSBC analyst M. Herholdt anticipates that the biotechnology company will earn $16.06 per share for the year. HSBC has a “Reduce” rating and a $150.00 price target on the stock. The consensus estimate for Biogen’s current full-year earnings is $15.82 per share. HSBC also issued estimates for Biogen’s FY2027 earnings at $16.26 EPS, FY2028 earnings at $16.67 EPS and FY2029 earnings at $16.23 EPS.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same period in the prior year, the business earned $3.44 EPS. The firm’s revenue for the quarter was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS.

A number of other research analysts also recently weighed in on BIIB. Wolfe Research set a $231.00 price target on Biogen in a research note on Monday, February 9th. Mizuho increased their price objective on Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. Wedbush increased their price objective on Biogen from $187.00 to $191.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 1st. Argus raised Biogen to a “hold” rating in a research note on Thursday, April 9th. Finally, Piper Sandler raised Biogen from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $177.00 to $214.00 in a research note on Tuesday, April 14th. Fourteen investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Biogen presently has an average rating of “Hold” and a consensus target price of $209.77.

Biogen Stock Up 2.2%

BIIB stock opened at $190.07 on Wednesday. The stock’s 50 day simple moving average is $185.53 and its 200 day simple moving average is $174.73. Biogen has a fifty-two week low of $115.25 and a fifty-two week high of $202.41. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The company has a market cap of $27.89 billion, a P/E ratio of 21.57, a price-to-earnings-growth ratio of 2.48 and a beta of 0.16.

Institutional Trading of Biogen

A number of institutional investors and hedge funds have recently modified their holdings of the business. Rothschild Investment LLC increased its position in shares of Biogen by 12.3% during the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 56 shares during the last quarter. Itau Unibanco Holding S.A. boosted its stake in Biogen by 24.4% in the fourth quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 66 shares during the last quarter. Advisory Services Network LLC boosted its stake in Biogen by 3.9% in the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after acquiring an additional 68 shares during the last quarter. CVA Family Office LLC boosted its stake in Biogen by 18.1% in the third quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 71 shares during the last quarter. Finally, Davis Investment Partners LLC boosted its stake in Biogen by 1.7% in the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after acquiring an additional 71 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the sale, the insider directly owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.18% of the company’s stock.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: UBS upgraded BIIB to Buy from Neutral and raised its price target to $225, citing a “slew of pipeline catalysts” across the next 12–15 months (readouts and commercialization milestones that could meaningfully re‑rate the stock). Biogen upgraded by UBS on ‘slew of pipeline catalysts’ going into 2027
• Positive Sentiment: Biogen secured Greater China rights to felzartamab (the immune‑disease antibody) — the deal gives Biogen another late‑stage asset as global phase IIIs progress and supports commercial optionality in a large market. BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up
• Positive Sentiment: Biogen announced a strategic deal with TJ Biopharma (transaction details reported to expand Biogen’s pipeline/partnership footprint), which traders viewed as supportive of near‑term momentum. Biogen Zooms on Deal with TJ Biopharma
• Neutral Sentiment: Analyst commentary and aggregator coverage (TipRanks/press summaries) amplify the UBS thesis (mentions of Apellis acquisition and valuation discount), reinforcing the bullish narrative but largely repeating the same catalysts. Biogen: Underappreciated Late‑Stage Pipeline, Apellis Acquisition…
• Negative Sentiment: HSBC maintains a Reduce rating and a $150 target, publishing conservative multi‑year EPS forecasts — a counterpoint to UBS that highlights downside risk if pipeline readouts or commercial execution disappoint. MarketBeat Biogen coverage (HSBC estimates)
• Negative Sentiment: A Zacks earnings preview warns Q1 revenue/earnings may decline vs. year‑ago levels, reminding investors of near‑term volatility and execution risk ahead of upcoming results. Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.